$TCRT
Alaunos Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024097142 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $4.000K
YoY Change 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.007M $990.0K
YoY Change -71.87% -67.49%
% of Gross Profit
Research & Development $143.0K $180.0K
YoY Change -96.09% -96.53%
% of Gross Profit
Depreciation & Amortization $0.00 $1.000K
YoY Change -100.0% -99.86%
% of Gross Profit
Operating Expenses $1.150M $1.170M
YoY Change -86.73% -85.35%
Operating Profit -$1.150M -$1.166M
YoY Change -86.73% -85.39%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $23.00K $37.00K
YoY Change -87.77% -104.68%
Pretax Income -$1.127M -$1.129M
YoY Change -86.71% -87.13%
Income Tax
% Of Pretax Income
Net Earnings -$1.127M -$1.129M
YoY Change -86.7% -87.13%
Net Earnings / Revenue -28225.0%
Basic Earnings Per Share -$0.70 -$0.71
Diluted Earnings Per Share -$0.70 -$0.71
COMMON SHARES
Basic Shares Outstanding 1.601M 16.01M
Diluted Shares Outstanding 1.601M 1.601M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.683M $2.463M
YoY Change -85.86% -86.55%
Cash & Equivalents $1.683M $2.463M
Short-Term Investments
Other Short-Term Assets $1.867M $2.211M
YoY Change 107.44% 383.81%
Inventory
Prepaid Expenses
Receivables $0.00 $4.000K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.550M $4.678M
YoY Change -72.41% -75.09%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $3.550M $4.678M
Total Long-Term Assets $0.00 $0.00
Total Assets $3.550M $4.678M
YoY Change -81.74% -83.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $458.0K $365.0K
YoY Change -64.71% -75.32%
Accrued Expenses $368.0K $542.0K
YoY Change -88.02% -83.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $826.0K $907.0K
YoY Change -82.34% -82.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $826.0K $907.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $826.0K $907.0K
YoY Change -85.09% -85.55%
SHAREHOLDERS EQUITY
Retained Earnings -$919.7M -$918.6M
YoY Change 1.3% 2.13%
Common Stock $922.4M $922.3M
YoY Change 0.07% 0.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.724M $3.771M
YoY Change
Total Liabilities & Shareholders Equity $3.550M $4.678M
YoY Change -81.74% -83.25%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$1.127M -$1.129M
YoY Change -86.7% -87.13%
Depreciation, Depletion And Amortization $0.00 $1.000K
YoY Change -100.0% -99.86%
Cash From Operating Activities -$781.0K -$1.681M
YoY Change -87.76% -75.99%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -781.0K -1.681M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -781.0K -1.681M
YoY Change -87.76% -91.21%
FREE CASH FLOW
Cash From Operating Activities -$781.0K -$1.681M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$781.0K -$1.681M
YoY Change -87.76% -76.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33038
dei Entity Registrant Name
EntityRegistrantName
Alaunos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
dei Entity Address Address Line1
EntityAddressAddressLine1
2617 Bissonnet Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 225
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77005
dei City Area Code
CityAreaCode
346
dei Local Phone Number
LocalPhoneNumber
355-4099
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TCRT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1601252
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2463000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6062000
CY2024Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
4000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2211000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2198000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
4678000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8261000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2024Q2 us-gaap Assets
Assets
4678000
CY2023Q4 us-gaap Assets
Assets
8263000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
365000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
616000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
542000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1340000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
907000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1956000
CY2024Q2 us-gaap Liabilities
Liabilities
907000
CY2023Q4 us-gaap Liabilities
Liabilities
1956000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1601252
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1601252
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1601252
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1601252
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
922346000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
922072000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-918577000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-915767000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3771000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6307000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4678000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8263000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
180000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5186000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
306000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11689000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
990000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3045000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2607000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6213000
CY2024Q2 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
CY2023Q2 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
245000
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
245000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1170000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
7986000
us-gaap Operating Expenses
OperatingExpenses
2913000
us-gaap Operating Expenses
OperatingExpenses
17657000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1166000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7982000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2907000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17653000
CY2024Q2 us-gaap Interest Expense
InterestExpense
0
CY2023Q2 us-gaap Interest Expense
InterestExpense
1068000
us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
1921000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
37000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
277000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
97000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
753000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-791000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
97000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1168000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1129000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8773000
us-gaap Net Income Loss
NetIncomeLoss
-2810000
us-gaap Net Income Loss
NetIncomeLoss
-18821000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.78
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1601252
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1601252
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1598650
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1598650
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1601252
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1601252
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1598258
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1598258
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4798000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1129000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3771000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6307000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
274000
us-gaap Net Income Loss
NetIncomeLoss
-2810000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3771000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
29509000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
914000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8773000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
21650000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38555000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1824000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92000
us-gaap Net Income Loss
NetIncomeLoss
-18821000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
21650000
us-gaap Net Income Loss
NetIncomeLoss
-2810000
us-gaap Net Income Loss
NetIncomeLoss
-18821000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
1395000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1339000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
274000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
1824000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
0
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-947000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
245000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
3000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-342000
tcrt Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
0
tcrt Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
41000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-251000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
90000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-798000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2095000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
0
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1182000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-28000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3598000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16383000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
196000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
38000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
18105000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
125000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-18138000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3598000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34679000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6062000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52996000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2464000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18317000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
2063000
CY2023Q3 tcrt Strategic Advisor Name
StrategicAdvisorName
Cantor
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2500000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-918900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assesses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2024Q1 tcrt Pre Stock Split Shares Authorized
PreStockSplitSharesAuthorized
520000000
CY2024Q1 tcrt Post Stock Split Shares Authorized
PostStockSplitSharesAuthorized
34666667
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Second Charter Amendment became effective on January 31, 2024.
CY2024Q3 tcrt Pre Stock Split Shares Authorized
PreStockSplitSharesAuthorized
34666667
CY2024Q3 tcrt Post Stock Split Shares Authorized
PostStockSplitSharesAuthorized
5000000
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Third Charter Amendment became effective on July 17, 2024.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
175476
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
247921
CY2018Q4 tcrt Maximum Royalty Amount
MaximumRoyaltyAmount
100000000
CY2024Q2 us-gaap Royalty Expense
RoyaltyExpense
0
us-gaap Royalty Expense
RoyaltyExpense
0
CY2023Q1 us-gaap Loss Contingency Name Of Plaintiff
LossContingencyNameOfPlaintiff
KBI Biopharma
CY2023Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3200000
CY2023Q4 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1000000
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
101000
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
914000
us-gaap Share Based Compensation
ShareBasedCompensation
273000
us-gaap Share Based Compensation
ShareBasedCompensation
1824000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
6288
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.72
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4133
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10289
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
24567
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
58.5
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0409
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0351
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0387
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.1465
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.705
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8969
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9563
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46589
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
268.5
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M20D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10289
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
26641
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
283.08
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
30237
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
168.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M15D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
17743
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
250.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
145745

Files In Submission

Name View Source Status
tcrt-20240630_htm.xml Edgar Link completed
0000950170-24-097142-index-headers.html Edgar Link pending
0000950170-24-097142-index.html Edgar Link pending
0000950170-24-097142.txt Edgar Link pending
0000950170-24-097142-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
tcrt-20240630.htm Edgar Link pending
tcrt-20240630.xsd Edgar Link pending
tcrt-ex31_1.htm Edgar Link pending
tcrt-ex32_1.htm Edgar Link pending